Introduction {#Sec1}
============

Salivary gland carcinoma is a rare tumor entity including a variety of different histologic subgroups \[[@CR1]\]. Large retrospective studies provide evidence suggesting a benefit of postoperative external beam radiotherapy in locally advanced salivary gland cancer \[[@CR2], [@CR3]\]. Especially in patients with perineural invasion and/or positive resection margins locoregional tumor control after surgery is low \[[@CR2]--[@CR4]\]. Moreover adenoidcystic carcinoma (ACC) is known as a radioresistant tumor and in case of macroscopic tumor high LET (linear energy transfer) radiation with protons or especially carbon ions might be beneficial \[[@CR5]--[@CR7]\]. In recent times high LET radiation was also investigated in patients with all kinds of salivary gland carcinomas in case of high-risk features (positive resection margin and/or perineural invasion) in the postoperative situation \[[@CR8]--[@CR10]\].

Of the large retrospective studies that support effectiveness of postoperative photon radiotherapy \[[@CR11]\] in patients with locally advanced SGC there is no study that only investigates patients with the high-risk features perineural spread and/or positive resection margins like those patients who met inclusion citeria for participating in trials using carbon ion radiotherapy in the postoperative situation. The purpose of this retrospective monocentric analysis was to evaluate local/locoregional control (LC/LRC) in patients with salivary gland carcinoma with microscopic or grossly positive (R1/R2) resection margins and/or perineural invasion after postoperative radio (chemo) therapy with photons. Therefore we reviewed all patients with salivary gland carcinoma with positive resection margin and/or perineural spread, who underwent postoperative radio (chemo) therapy in our department between 2000 and 2017.

Material and methods {#Sec2}
====================

Data collection, patient characteristics {#Sec3}
----------------------------------------

We reviewed clinical records of patients with newly diagnosed locally advanced salivary gland carcinoma of the head and neck region who were treated with surgery followed by radio (chemo) therapy from January 2000 until April 2017. Only patients with perineural invasion (Pn1) and/or positive resection margins (R1/R2 resection) were included in the analysis. Moreover patients with distant metastases at the date of first diagnosis, patients with squamous cell carcinoma or patients who underwent brachytherapy alone were excluded.

For detailed patient information see Table [1](#Tab1){ref-type="table"}:Table 1Patient characteristicsPatients' characteristics (*n* = 65)CharacteristicsValue%Gender (Number of patients) female3046.2% male3553.8%Age at diagnosis (years) Median57 Range26--83Primary tumor site (Number of patients) Parotid Gland3655.4% Submandibular Gland1116.9% Minor Salivary Glands:1827.7% - Nasal cavity/paranasal sinus6 - Hard palate3 - Tongue/base of tongue5 - Meatus acusticus2 - Floor of mouth1 - Cheek1Histologic Subtypes (Number of patients) Adenoidcystic Carcinoma2538.5% Mucoepidermoid Carcinoma1320.0% Ductal Adenocarcinoma1929.2% Adenocarcinoma NOS46.2% Acinic cell carcinoma23.1% other23.1%Tumor stage (Number of Patients) pT1913.8% pT21015.4% pT33046.2% pT41624.6% pT4a13 pT4b3Primary tumor size (cm) Median:2.8 Range:1--8.5Nodal Stage (Number of Patients) c/pN02741.5% pN11421.5% pN2b2436.9%Perinodal Spread (Number of Patients) no3960.0% yes2132.3% unknown57.7%Lymphangiosis (Number of patients) L04366.2% L12030.8% Lx23.1%Hemangiosis (Number of patients) V05280.0% V11116.9% Vx23.1%Perineural Spread (Number of Patients) Pn069.2% Pn15990.8%Resection margin (Number of Patients) R04061.5% R11929.2% R269.2%Grade of Differentiation (Number of Patients) Low-grade69.2% Intermediate-grade1116.9% High-grade4772.3% Gx11.5%Bone Infiltration of primary tumor No5990.8% Yes69.2%Neck Dissection (Number of Patients) None1015.4% Ipsilateral4873.8% Bilateral710.8%Radio (chemo) therapy (Number of patients) Radiation alone2436.9% Radiochemotherapy4163.1%Radiation dose (Gy): Median: 64 Range: 45--74.2GyRadiation technique (Number of patients) 3D:3858.5% IMRT:2741.5%Planning target volume (number of patients) Primary tumor region1116.9% Primary tumor region, ipsilateral neck3553.8% Primary tumor region, bilateral neck1929.2%

Treatment {#Sec4}
---------

All patients were treated with surgery followed by radiotherapy or radiochemotherapy with curative intention. Local resection of primary tumor was performed in all patients. A second primary tumor resection was necessary in 14 patients (21.5%). Resection margin was negative in 40 patients (61.5%) and microscopically positive in 19 patients and 6 patients had a macroscopically positive resection margin in the final pathologic results. 48 (73.8%) patients underwent ipsilateral neck dissection alone, 7 patients (10.8%) underwent bilateral neck dissection and in 10 (15.4%) patients no neck dissection was performed. Forty-one patients (63.1%) received chemotherapy simultaneously. Of these 41 patients 38 patients received platinum-based and 3 patients mitomycin c based chemotherapy. Usually chemotherapy was recommended for patients with locally advanced T-stage T3/4, high grade disease, lymph node metastases with perinodal spread, ≥3 lymph node metastasis or positive/close resection margins. Patients with these tumor characteristics, who did not receive additional chemotherapy, either refused chemotherapy or suffered from comorbidities (1 patient), that did not allow chemotherapy .

The median radiotherapy dose administered was 64 Gy (range: 45Gy; 74.2Gy).

Target volume delineation was performed on a contrast-enhanced computed tomography scan. The preoperative CT and/or MRI scan was fused to the planning CT.

CTV always included the primary tumor region along the nerve tracts up to the base of skull. In case of positive ipsilateral neck nodes ipsilateral lymph nodes were included and if the primary tumor was located at or crossing the midline or patients had multiple ipsilateral lymph node metastases with extracapsular extension, bilateral nodes were included.

After treatment patients had regular follow-up visits in our department as well as in the department of otorhinolaryngology. Usually these visits occurred every 3 months in the first 2 years after treatment, then every 6 months and after 5 years patients had yearly follow-up visits. Usually patients underwent an ENT examination and an ultrasound of the neck at every visit. Every 6 months in the first 5 years patients received an x-ray or CT of the chest (CT usually including the upper stomach). In case of symptoms diagnostic imaging was performed immediately.

Statistics/analysis of data {#Sec5}
---------------------------

Overall survival and disease-free-survival as well as the cumulative incidence of locoregional-recurrence and distant metastases were scored from the time of first diagnosis (defined as the date of biopsy or surgery of the primary tumor). Disease-free survival was defined as the absence of locoregional or distant disease recurrence and death from any cause. Statistical analysis was performed using the SPSS software version 21. The Kaplan-Meier-Method was used for calculating estimated overall-survival, disease-free-survival and the cumulative incidence of local/locoregional control and distant metastases. In univariate analysis the log-rank-test was used to correlate patient- tumor- and treatment-related parameters with overall-survival, disease-free-survival, incidence of local/loregional recurrences and distant metastases. Therefore the following dichotome risk-classification of the different variables was used considering the limited number of patients: gender; age (\< 70 years, ≥70 years); adenoidcystic vs. non-adenoidcystic carcinoma; tumor site (parotid vs non-parotid); T-stage(T1/2 vs T3/4); tumor size(≤3 cm vs \> 3 cm); N-stage (N0 vs N1/2); number of metastatic lymph nodes: \> 1 vs. ≤ 1; extranodal extension; perineural spread; lymphovascular/vascular invasion; high vs. low/intermediate grade; resection margin(R0 vs R1/2; R0/1 vs. R2); neck dissection; number of dissected lymph nodes (≥10 vs. \< 10;); Lymph node density (≤4 vs \> 4), second primary tumor resection; applied radiation dose (\<64Gy vs ≥64Gy), radiation technique (3D vs. IMRT). Only variables yielding *p*-values of ≤0,05 were subsequently included in the multivariate analysis. For multivariate analysis the cox regression analysis was used.

A two-sided p-value \<0,05 was considered to be statistically significant.

Results {#Sec6}
=======

Median follow-up was 45 months (range: 6; 215). Of the 65 patients perineural spread was present in 59 patients and positive resection margins in 25 patients, 19 patients showed perineural spread and a positive resection margin.

Of the 65 patients included in the analysis, seven (10.8%) developed local relapse and 28 (43.1%) developed distant metastases .

At the last follow-up, 29 patients (44.6%) were still alive and free from recurrence.

Local/Locoregional recurrence {#Sec7}
-----------------------------

Cumulative incidence of local recurrence (see Fig. [1](#Fig1){ref-type="fig"}) and locoregional recurrence (see Fig. [2](#Fig2){ref-type="fig"}) was 3.1, 7.0, 7.0% and 3.1, 9.7, 12.9% after 1, 3 and 5 years.Fig. 1Cumulative incidence of local recurrenceFig. 2Cumulative incidence of locoregional recurrence

The only parameter correlating significantly with the incidence of local (see Fig. [3a](#Fig3){ref-type="fig"}) recurrence was a macroscopic resection margin (*p* = 0.002). In univariate analysis gender (*p* = 0.05) and a macroscopic resection margin (*p* = 0.031) were significantly associated with decreased locoregional control. For detailed information see in the [Appendix](#Sec13){ref-type="sec"} in Table 3. In multivariate analysis only a macroscopic resection margin remained a significant predictor (*p* = 0.04) (see Fig. [3b](#Fig3){ref-type="fig"}). Three of the 40 patients with R0 resection, 2 of the 19 patients with microscopic positive resection margin and 2 of the 6 patients with grossly positive resection margin developed a locoregional recurrence. In this context it should be noted that one of the 2 grossly positive resected patients who developed a local recurrence had the R2 situation not in the primary tumor region but in the cervical lymph nodes.Fig. 3Cumulative incidence of local (3**a**) and locoregional (3**b**) recurrence according to resection margin

There was a trend towards superior local control for intensity-modulated radiotherapy in comparison to 3D-conformal radiotherapy (*p* = 0.099).

Overall locoregional recurrences were diagnosed in 7 patients. Five of these patients also developed distant metastases, whereas in 2 patients synchronous distant metastases occurred, in one patient distant metastases were already known 18 months before occurrence of locoregional recurrence and in two patients distant metastases were diagnosed after diagnosis of locoregional recurrence. Four of these 7 recurrences were in-radiation-field recurrences while the remaining 2 were outside the radiation field (one in the contralateral lymph nodes, one in the thyroid gland) and one in the margin of the radiation field: the sinus cavernosus (for detailed information see Table [2](#Tab2){ref-type="table"}).Table 2Locoregional recurrencesPatientTumor histology /stageLocalisation of locoregional recurrenceIn-FieldPat.1\
(male)High-grade mucoepidermoid carcinoma of the parotid gland\
pT3pN1(1/18)L1V1Pn1R0Gingiva, Mandibula with infiltration of the skin, also disseminated lung metastases at the timepoint of diagnosis of locoregional recurrenceyesPat.2\
(male)Ductal adenocarcinoma of the parotid gland, high-grade\
pT4pN2b(19/38)L1V0Pn1\
R2 (detection of supraclavicular lymph node metastases before start of radiochemotherapy)Recurrence in the parotid region with orbital infiltration, also disseminated bone metastases at the timepoint of diagnosis of locoregional recurrenceyesPat.3\
(male)Intermediate-grade mucoepidermoid carcinoma of the parotid gland\
pT1pN2b(2/3)L0V0Pn0R1Recurrence in the parotid region (R0 resection of recurrence was possible)yesPat.4\
(male)Low-grade adenoidcystic carcinoma of the submandibular gland\
pT3pN0(0/34)L0V0Pn1R1Recurrence in the thyroid gland, diagnosis of lung metastases 13 months after diagnosis of locoregional recurrenceNoPat.5\
(male)Ductal carcinoma of the parotid gland, high-grade\
pT4pN2b(22/28)LxVxPn1R0Contralateral lymph node metastases, diagnosis of lung and liver metastases 6 months after diagnosis of locoregional recurrencenoPat.6\
(female)High-grade adenoidcystic carcinoma of the sinus maxillaris on the left side with skull base and orbital infiltration\
pT4cN1R2Recurrence in sinus maxillarisyesPat.7\
(male)High grade adenoidcystic arcinoma of the submandibular gland on the left side\
pT3 pN0 (0/24) cM0 L0 V0 Pn1 R0Recurrence in Sinus cavernosus, also disseminated lung metastases diagnosed 18 months before diagnosis of locoregional recurrenceMargin of radiation field

Overall and disease-specific survival {#Sec8}
-------------------------------------

OS was 90.5, 74.9 and 63.9% after 1, 3 and 5 years. Disease-specific survival was 93.6, 80.8 and 71.0% after 1, 3 and 5 years.

Disease-free survival {#Sec9}
---------------------

DFS was 83.0, 54.8 and 49.4% after 1, 3 and 5 years (see Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Disease-free survival

In univariate analysis high-grade histology (*p* = 0.014) was the only significant predictor for a decreased DFS. In patients with low-or intermediate grade salivary gland carcinoma DFS was 100, 82.4, 82.4% after 1,3 and 5 years while in patients with high-grade histology DFS was 76.4, 44.0, 35.8% after 1,3 and 5 years.

Distant metastases {#Sec10}
------------------

Cumulative incidence of distant metastases was 15.6, 36.0 and 44.0% after 1, 3 and 5 years (see Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Cumulative incidence of distant metastases

Distant metastases were found in the following locations: lung: *n* = 19 patients, bone: *n* = 3 patients, liver: *n* = 2 patients, disseminated: *n* = 4 patients.

In univariate analysis an advanced T-Stage (*p* = 0.031), high-grade histology (*p* = 0.006) and the presence of extracapsular extension of lymph node metastases (*p* = 0.044) was associated with an increased incidence of distant metastases. In multivariate analysis none of the variables reached statistical significance.

Discussion {#Sec11}
==========

This study evaluates the outcome of patients with salivary gland carcinoma (SGC) with positive resection margin and/or perineural invasion after photon (chemo-)radiotherapy. Because of the rarity of SGC no prospective study on the impact of radiotherapy in the postoperative situation is available. There is evidence from large retrospective studies and experience from single centre evaluations that show a benefit of postoperative radiotherapy in patients with SGC with high-risk features \[[@CR2], [@CR3]\]. In retrospective studies a positive resection margin and/ or perineural spread were identified as risk factors for locoregional recurrence of salivary gland cancer \[[@CR2]--[@CR4]\].

To the best of our knowledge this is the only retrospective analysis of the impact of photon (chemo) radiotherapy in patients with SGC after surgery, which only includes patients with positive resection margin and/or perineural spread.

This retrospective study shows high local and locoregional control rates of over 93 and 87.1% after 5 years in a high-risk population of patients with salivary gland carcinoma. In 7 out of 65 patients locoregional recurrence occurred.

The COSMIC trial \[[@CR8]--[@CR10]\] investigates the effect of carbon ion radiotherapy in all kinds of SGC including patients with microscopic resection margins defined as microscopically positive resection margin and/or showing perineural spread (referred to as R1-group). Preliminary results of the cosmic trial show a locoregional control rate of 89.7%/ 86.9% and a PFS of 64.6%/58.8% after 3 years in the R1/R2 group compared to a locoregional control rate of 87.1% and a DFS of 54.8% after 3 years in our retrospective analysis.

It has to be mentioned that some patient characteristics were different in the COSMIC trial in comparison to our study. First of all 14 of the 20 patients (70%) in the group with microscopic positive resection margin and all patients of the group with macroscopic positive resection margin of the cosmic trial were patients with adenoidcystic carcinomas. The authors of the study state that "there were no significant differences between ACC and non-ACC histologic features regarding LC, PFS or OS." In our analysis 38.5% of patients had an adenoidcystic carcinoma, followed by patients with salivary duct carcinoma (29%) and mucoepidermoid carcinoma (20%). The high percentage of salivary duct carcinomas, which are known for their high rate of developing distant metastases \[[@CR12]--[@CR14]\] during follow-up, might explain the decreased disease-free survival in our study. Moreover in our patient population most patients had salivary gland cancer of the parotid gland (55%) whereas in the cosmic trial most of the patients had their primary tumor located in a minor salivary gland (especially paranasal sinus and palate).

Nevertheless, our results show a high local and locoregional control rate in patients with salivary gland carcinoma independent of tumor type and tumor location. The only significant predictor for decreased local and locoregional control was a macroscopic resection margin. There were, however, only 6 patients with an R2 resection in our analysis. Two of these patients developed local recurrence, with one of these patients having the R2 situation not in the primary tumor region, where the recurrence occurred, but in the cervical lymph nodes. Moreover it is worth noting, that the locoregional control rate of our analysis is comparable to that of the R1 group of the COSMIC trial. In the R1 group of the COSMIC trial no patients with macroscopic tumor margin were included.

Despite the high locoregional control rate DFS was only 49.4% after 5 years, because of a high rate of distant failure (44% after 5 years). Interestingly, in the Cosmic trial the first site of failure was also distant (\> 50% of the patients). Moreover other retrospective trials \[[@CR15]--[@CR17]\] report high rates of distant metastases in up to 47.3% of patients with salivary gland cancer, especially in high-grade carcinomas. Considering the high rates of locoregional control it is doubtful whether carbon ion radiotherapy is superior to photon radiotherapy in patients with salivary gland cancer with microscopically positive resection margins and/or perineural spread. In patients with macroscopic resection margin carbon ion radiotherapy might be considered.

Intensity-modulated radiotherapy showed a trend towards improved local control when compared to 3D-conformal radiation. None of the patients in the IMRT group developed a local recurrence, but follow-up is shorter in this group than in the 3d-conformal group.

The implementation of IMRT in recent years in combination with image-guided radiotherapy and their continuous development has led to the possibility of dose escalation in the tumor region while simultaneously reducing radiation dose at the organs at risk \[[@CR18]--[@CR25]\]. Especially in critical regions like the skull base highly conformal radiotherapy with IMRT might be beneficial \[[@CR26], [@CR27]\]. This means that in our patient population local control might even have been higher, if all patients had been treated with IMRT. Patients that were treated with 3D-conformal radiotherapy are not comparable to patients treated with carbon ion radiotherapy.

In this analyses high-grade histology is the only significant predictor for a decreased DFS as also reported in a previous study \[[@CR28]\]. Furthermore patients with high-grade histology, an advanced T-stage and the presence of extracapsular extension of lymph node metastases show a significant higher rate of distant metastases during follow-up. These findings are in line with the literature \[[@CR4], [@CR16], [@CR28]\]. An advanced T-Stage is associated with a higher rate of distant metastases but not with a decreased local control. It may therefore be assumed that in patients with an advanced T-stage und additional risk factors like positive resection margin and/or perineural spread, the risk of development of distant metastases is much higher than that of experiencing locoregional recurrence.

Laramore et al. \[[@CR29]\] in their final report on the RTOG trial comparing definitive neutron and photon radiotherapy stated, that local control was increased by neutron therapy, but that this did not translate into an improved overall survival, because of the high rate of distant metastases during follow-up.

In future the real challenge will therefore be to investigate intensified first-line systemic treatments to decrease the rate of distant metastases.

It also has to be mentioned, that this study has several limitations. First of all the evaluation we performed was retrospective with a small number of patients and with a heterogeneous mix of different tumor subtypes and sites, which makes the evaluation of treatment outcome more difficult. Moreover because of the retrospective nature of our study the times at which radiologic imaging was performed were not clearly defined and might have influenced the survival analysis. Radiation techniques have changed over the last few years. The implementation of intensity-modulated radiotherapy in combination with image-guided radiotherapy has led to higher treatment accuracy and to the possibility of applying higher doses to the tumor region. Therefore the fact that we included patients, who were irradiated using 3D-conformal techniques may have led to lower locoregional control rates in our study. It is doubtful if a multivariate analysis makes sense considering the small number of patient. Toxicity was not assessed. This could be a potential advantage ofproton or carbon ion radiotherapy over radiotherapy with photons.

Despite these shortcomings this retrospective study shows that in patients with salivary gland carcinoma high local and locoregional control rates are achieved even in patients with positive microscopic resection margins and/or perineural spread after postoperative radiotherapy with photons. In the future the real challenge in the treatment of salivary gland cancer will be the optimization of systemic treatment options to decrease distant failure.

Conclusion {#Sec12}
==========

Photon radiotherapy leads to high local and locoregional control rates in a high-risk patient population with SGC with microscopically positive resection margins and/or perineural spread. The most common site of disease recurrence was distant metastases. Therefore the real challenge for the future should be to prevent distant metastases.

Appendix {#Sec13}
========

Table 3Patient-, tumor-and treatment-related factors compared to local and locoregional recurrencesUnivariate***Local recurrence***\
***p-value***\
Hazard ratio\
(95% confidence interval)***Locoregional recurrence***\
***p-value***\
Hazard ratio\
(95% confidence interval)Patient-dependent Gender**0.3890.050**  female vs. male0.38 (0.04--3.69)0.16 (0.02--1.31) Age at diagnosis**0.8390.828**  ≥70y vs. \<70y1.27 (0.13--12.24)0.79 (0.09--6.68)Tumor-related Primary tumor site**0.3680.664**  non-parotid vs. parotid0.37 (0.04--3.54)0.72 (0.16--3.23) Histologic Subtype**0.5410.953**  non-adenoidcystic vs.2.000.956  adenoid cystic(0.21--19.21)(0.21--4.29) T classification**0.7730.196**  T3/4 vs. T1/21.39 (0.15--13.43)3.75 (0.44--31.85) Primary tumor size, cm**0.7030.711**  \>3 cm vs. ≤ 3 cm0.63 (0.06--6.95)1.35 (0.27--6.72) N classification**0.0750.227**  N1/2 vs. N053.2 (0.02--180,704.08)2.68 (0.51--14.09) Number of metastatic lymph nodes**0.2850.224**  \>1 vs. ≤ 13.42 (0.31--37.85)2.68 (0.52--13.88) Histological tumor grade**0.7470.537**  High vs. low/intermediate1.20 (0.39--3.75)1.30 (0.56--2.99) Extranodal extension**0.2280.581**  yes vs. no0.03 (0.00--656.48)0.55 (0.06--4.78) Perineural Spread**0.2220.403**  yes vs. no0.27 (0.03--2.60)0.41 (0.05--3.51)Lymphovascular invasion**0.1630.587**yes vs. no4.72 (0.43--52.22)1.64 (0.27--9.82) Vascular invasion**0.3800.680**  yes vs. no2.80 (0.25--31.05)1.58 (0.18--14.23) Bone invasion**0.2220.603**  yes vs. no3.72 (0.39--36.03)1.75 (0.21--14.60)Treatment-related Resection margin**0.1190.179**  R1/2 vs. R05.04 (0.52--48.53)2.81 (0.62--12.72) Resection margin**0.0020.031**  R2 vs R0/111.26 (1.58--80.45)5.15 (0.98--26.93) Second primary tumor resection**0.2930.543**  yes vs. no0.034 (0.00--910.95)0.52 (0.06--4.37) Neck Dissection**0.5980.852**  yes vs. no0.55 (0.06--5.28)1.22 (0.15--10.18) Number of dissected nodes**0.6750.708**  ≥10 vs. \< 100.60 (0.05--6.64)1.50 (0.18--12.88) Lymph node density (%)**0.1100.246**  \>4 vs. ≤456.27 (0.01--637,456.03)2.71 (0.48--15.42) Radiation dose**0.3330.698**  ≥64Gy vs. \<64Gy0.34 (0.04--3.31)0.66 (0.08--5.50) Planning target Volume**0.3180.108**  primary tumor region &28.57 (0.00--1,127,372.02)34.53 (0.03--47,010.85)  regional lymph drainage vs.  primary tumor region Radiation technique**0.0990.226**  IMRT vs. 3D0.02 (0.00--82.02)0.290 (0.03--2.45)

ACC

:   Adenoidcystic carcinoma

CT

:   Computer tomography

DFS

:   Disease-free survival

DM

:   Distant metastases

IMRT

:   Intensity-modulated radiotherapy

LC

:   Local control

LET

:   Linear energy transfer

LRC

:   Locoregional control

OS

:   Overall survival

PFS

:   Progression-free survival

Pn1

:   Perineural spread

R0 resection

:   complete resection

R1 resection

:   microscopically positive resection margins

R2 resection

:   macroscopically positive resection margins

SGC

:   Salivary gland cancer
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